| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRG3 |
| Uniprot No | Q9Y2Y8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-225aa |
| 氨基酸序列 | LHL ENDAPHLESL ETQADLGQDL DSSKEQERDL ALTEEVIQAE GEEVKASACQ DNFEDEEAME SDPAALDKDF QCPREEDIVE VQGSPRCKIC RYLLVRTPKT FAEAQNVCSR CYGGNLVSIH DFNFNYRIQC CTSTVNQAQV WIGGNLRGWF LWKRFCWTDG SHWNFAYWSP GQPGNGQGSC VALCTKGGYW RRAQCDKQLP FVCSF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRG3重组蛋白的3篇参考文献示例(注：文献为虚拟示例，实际文献需根据具体数据库检索确认)：
---
1. **文献名称**：*Recombinant PRG3 Enhances Neurite Outgrowth via RhoA Signaling in Cortical Neurons*
**作者**：Chen L, et al.
**摘要**：研究利用重组PRG3蛋白处理皮层神经元，发现其通过抑制RhoA通路促进神经突生长，表明PRG3在神经再生中的潜在应用价值。
2. **文献名称**：*PRG3 Recombinant Protein Suppresses Tumor Growth by Modulating Angiogenesis in Glioblastoma Models*
**作者**：Kim S, et al.
**摘要**：通过体外和体内实验证明，重组PRG3蛋白通过下调VEGF表达抑制胶质母细胞瘤血管生成，从而减缓肿瘤进展。
3. **文献名称**：*Expression and Functional Characterization of Human PRG3 in a Baculovirus System*
**作者**：Wang X, et al.
**摘要**：利用杆状病毒系统高效表达重组PRG3蛋白，并验证其与细胞表面硫酸肝素的结合活性，为后续机制研究提供工具。
---
如需真实文献，建议在PubMed、Google Scholar等平台检索关键词“PRG3 recombinant protein”或“PRG3 protein function”获取最新研究。
**Background of PRG3 Recombinant Protein**
PRG3 (Protease-Regulated Gene 3), also known as PRG3 or LOH11CR2A, is a protein-coding gene implicated in cellular processes such as proliferation, migration, and angiogenesis. Initially identified for its upregulated expression in certain cancers, including gliomas and colorectal cancer, PRG3 has drawn attention for its potential role in tumor progression and metastasis. The protein is characterized by a conserved collagen-like domain and a C-terminal cysteine-rich region, suggesting involvement in extracellular matrix interactions or signaling modulation.
Recombinant PRG3 refers to the engineered version of this protein, produced using heterologous expression systems (e.g., bacterial, mammalian, or insect cells). Its production enables precise study of PRG3's biochemical properties, interactions, and functional mechanisms. Studies indicate that PRG3 may regulate pathways like PI3K/Akt and MAPK, influencing cell survival and motility. Additionally, its overexpression in tumor-associated endothelial cells hints at a role in tumor vascularization, making it a potential therapeutic target.
The development of PRG3 recombinant protein has facilitated *in vitro* and *in vivo* research, including antibody generation, receptor binding assays, and functional studies in cancer models. Its applications extend to exploring diagnostic or prognostic biomarkers and designing targeted therapies to inhibit PRG3-driven pathways. However, comprehensive mechanistic insights and clinical relevance remain under investigation, necessitating further research to harness its full biomedical potential.
In summary, PRG3 recombinant protein serves as a critical tool for unraveling the biological and pathological roles of PRG3. bridging molecular insights with translational opportunities in oncology and beyond.
×
